{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:15:23Z","timestamp":1778040923393,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences"},{"name":"the foundation of National Natural Science Foundation of China"},{"name":"the foundation of Natural Science Foundation of Shandong"},{"name":"Taishan Scholars Program"},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Youth Foundation Cultivation Project of Shandong First Medical University"},{"name":"Collaborative Academic Innovation Project of Shandong cancer hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-026-01024-w","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:09:03Z","timestamp":1774616943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["[18F]AlF-NOTA-QHY-04 uptake in spleen before anti-tumor therapy may predict degree of myelosuppression for patients with small cell lung cancer"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4466-9995","authenticated-orcid":false,"given":"Siyu","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengnan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinli","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunlong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2931-2756","authenticated-orcid":false,"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"1024_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1024_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primer. 2021;7:3.","journal-title":"Nat Rev Dis Primer"},{"key":"1024_CR3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1186\/s12885-021-09034-6","volume":"21","author":"S Jiang","year":"2021","unstructured":"Jiang S, Huang L, Zhen H, Jin P, Wang J, Hu Z. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. BMC Cancer. 2021;21:1308.","journal-title":"BMC Cancer"},{"issue":"14","key":"1024_CR4","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","volume":"30","author":"R A","year":"2012","unstructured":"A R, M DM. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692\u20138.","journal-title":"J Clin Oncol"},{"key":"1024_CR5","unstructured":"Joel SP, Shah R, Slevin ML, Suppl. S69\u201375."},{"key":"1024_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0749-2081(92)90027-Z","volume":"8","author":"MB Maxwell","year":"1992","unstructured":"Maxwell MB, Maher KE. Chemotherapy-induced myelosuppression. Semin Oncol Nurs. 1992;8:113\u201323.","journal-title":"Semin Oncol Nurs"},{"key":"1024_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1177\/0897190014546108","volume":"27","author":"JN Barreto","year":"2014","unstructured":"Barreto JN, McCullough KB, Ice LL, Smith JA. Antineoplastic agents and the associated myelosuppressive effects: a review. J Pharm Pract. 2014;27:440\u20136.","journal-title":"J Pharm Pract"},{"key":"1024_CR8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nri1669","volume":"5","author":"RE Mebius","year":"2005","unstructured":"Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005;5:606\u201316.","journal-title":"Nat Rev Immunol"},{"key":"1024_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/MNM.0b013e3283595cac","volume":"34","author":"K Pak","year":"2013","unstructured":"Pak K, Kim S-J, Kim IJ, Kim DU, Kim K, Kim H. Impact of cytokines on use splenic 18F-fluorodeoxyglucose uptake during positron emission tomography\/computed tomography. Nucl Med Commun. 2013;34:64\u201370.","journal-title":"Nucl Med Commun"},{"key":"1024_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/RLU.0b013e3181ef0905","volume":"35","author":"H-Y Nam","year":"2010","unstructured":"Nam H-Y, Kim S-J, Kim I-J, Kim B-S, Pak K, Kim K. The clinical implication and prediction of diffuse splenic FDG uptake during cancer surveillance. Clin Nucl Med. 2010;35:759\u201363.","journal-title":"Clin Nucl Med"},{"key":"1024_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00259-009-1183-0","volume":"36","author":"PY Salaun","year":"2009","unstructured":"Salaun PY, Gastinne T, Bodet-Milin C, et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin\u2019s lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging. 2009;36:1813\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1024_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1053\/j.semnuclmed.2023.09.002","volume":"54","author":"L Lindenberg","year":"2024","unstructured":"Lindenberg L, Ahlman M, Lin F, Mena E, Choyke P. Advances in PET Imaging of the CXCR4 Receptor: [68Ga]Ga-PentixaFor. Semin Nucl Med. 2024;54:163\u201370.","journal-title":"Semin Nucl Med"},{"key":"1024_CR13","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s42255-023-00853-4","volume":"5","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xu M, Sun J, et al. Glycolytic neutrophils accrued in the spleen compromise anti-tumour T cell immunity in breast cancer. Nat Metab. 2023;5:1408\u201322.","journal-title":"Nat Metab"},{"key":"1024_CR14","first-page":"1687","volume":"63","author":"AK Buck","year":"2022","unstructured":"Buck AK, Haug A, Dreher N, et al. Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET. J Nucl Med Off Publ Soc Nucl Med. 2022;63:1687\u201392.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"1024_CR15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00259-017-3622-7","volume":"44","author":"A Watts","year":"2017","unstructured":"Watts A, Singh B, Basher R, et al. 68Ga-Pentixafor PET\/CT demonstrating higher CXCR4 density in small cell lung carcinoma than in non-small cell variant. Eur J Nucl Med Mol Imaging. 2017;44:909\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1024_CR16","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s00259-022-06059-2","volume":"50","author":"A Watts","year":"2023","unstructured":"Watts A, Singh B, Singh H, et al. [68Ga]Ga-Pentixafor PET\/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors\u2019 density by immunochemistry techniques. Eur J Nucl Med Mol Imaging. 2023;50:1216\u201327.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1024_CR17","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.7150\/thno.99025","volume":"14","author":"K Cheng","year":"2024","unstructured":"Cheng K, Wang S, Liu T, et al. PET imaging of CXCR4 expression using [18F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors. Theranostics. 2024;14:6337\u201349.","journal-title":"Theranostics"},{"key":"1024_CR18","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00259-023-06517-5","volume":"51","author":"J Pei","year":"2024","unstructured":"Pei J, Cheng K, Liu T, et al. Early, non-invasive detection of radiation-induced lung injury using PET\/CT by targeting CXCR4. Eur J Nucl Med Mol Imaging. 2024;51:1109\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1024_CR19","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. U.S. Department of Health and Human. Services, National Institutes of Health, National Cancer Institute; 2017. NIH Publication No. 17-5410."},{"key":"1024_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pro6.1201","volume":"7","author":"J Wang","year":"2023","unstructured":"Wang J, Li B. Chinese expert consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy (2023 edition). Precis Radiat Oncol. 2023;7:150\u20139.","journal-title":"Precis Radiat Oncol"},{"issue":"3","key":"1024_CR21","first-page":"785","volume":"21","author":"N Jiang","year":"2013","unstructured":"Jiang N, Chen XC, Zhao Y. Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.\u2002Support. Care Cancer. 2013;21(3):785\u201391.","journal-title":"Care Cancer"},{"key":"1024_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2141.2008.07514.x","volume":"144","author":"R Pettengell","year":"2009","unstructured":"Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol. 2009;144:677\u201385.","journal-title":"Br J Haematol"},{"key":"1024_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014;90:190\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11 Suppl 11","key":"1024_CR24","first-page":"27","volume":"17","author":"L Balducci","year":"2003","unstructured":"Balducci L. Myelosuppression and its consequences in elderly patients with cancer.\u2002Oncology. (Williston Park). 2003;17(11 Suppl 11):27\u201332.","journal-title":"(Williston Park)"},{"issue":"6","key":"1024_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1177\/107327480000700605","volume":"7","author":"L Balducci","year":"2000","unstructured":"Balducci L, Hardy CL, Lyman GH. Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control. 2000;7(6):539\u201347.","journal-title":"Cancer Control"},{"issue":"4","key":"1024_CR26","first-page":"850","volume":"23","author":"S Singh","year":"2005","unstructured":"Singh S, Parulekar W, Murray N, et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer.\u2002J. Clin Oncol. 2005;23(4):850\u20136.","journal-title":"Clin Oncol"},{"key":"1024_CR27","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1215\/15228517-2008-120","volume":"11","author":"TS Armstrong","year":"2009","unstructured":"Armstrong TS, Cao Y, Scheurer ME, et al. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro-Oncol. 2009;11:825\u201332.","journal-title":"Neuro-Oncol"},{"key":"1024_CR28","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1200\/JCO.2002.20.6.1491","volume":"20","author":"JA Sloan","year":"2002","unstructured":"Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20:1491\u20138.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1024_CR29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/0002-8703(86)90645-9","volume":"111","author":"MS Green","year":"1986","unstructured":"Green MS, Jucha E, Luz Y. Blood pressure in smokers and nonsmokers: epidemiologic findings. Am Heart J. 1986;111:932\u201340.","journal-title":"Am Heart J"},{"issue":"1","key":"1024_CR30","first-page":"89","volume":"123","author":"DB Petitti","year":"1986","unstructured":"Petitti DB, Kipp H. The leukocyte count: associations with intensity of smoking and persistence of effect after quitting.\u2002Am. J Epidemiol. 1986;123(1):89\u201395.","journal-title":"J Epidemiol"},{"key":"1024_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1539\/joh1959.35.98","volume":"35","author":"H Kondo","year":"1993","unstructured":"Kondo H, Kusaka Y, Morimoto K. Effects of lifestyle on hematologic parameters; I. Analysis of hematologic data in association with smoking habit and age. Sangyo Igaku. 1993;35:98\u2013104.","journal-title":"Sangyo Igaku"},{"key":"1024_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.arcmed.2004.02.001","volume":"35","author":"T Kawada","year":"2004","unstructured":"Kawada T. Smoking-induced leukocytosis can persist after cessation of smoking. Arch Med Res. 2004;35:246\u201350.","journal-title":"Arch Med Res"},{"key":"1024_CR33","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1158\/1078-0432.CCR-12-0728","volume":"18","author":"A-JM de Graan","year":"2012","unstructured":"de Graan A-JM, Loos WJ, Friberg LE, et al. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:4425\u201332.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"33","key":"1024_CR34","first-page":"eaau6085","volume":"4","author":"SM Lewis","year":"2019","unstructured":"Lewis SM, Williams A, Eisenbarth SC. Structure and function of the immune system in the spleen.\u2002Sci. Immunol. 2019;4(33):eaau6085.","journal-title":"Immunol"},{"issue":"5","key":"1024_CR35","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.cell.2020.02.036","volume":"184","author":"Y Han","year":"2021","unstructured":"Han Y, Liu Q, Hou J, et al. Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression. Cell. 2021;184(5):1392.","journal-title":"Cell"},{"key":"1024_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.arcmed.2009.04.003","volume":"40","author":"Y Wang","year":"2009","unstructured":"Wang Y, Meng Q, Qiao H, Jiang H, Sun X. Role of the Spleen in Cyclophosphamide-induced Hematosuppression and Extramedullary Hematopoiesis in Mice. Arch Med Res. 2009;40:249\u201355.","journal-title":"Arch Med Res"},{"key":"1024_CR37","doi-asserted-by":"crossref","unstructured":"Schwenck J, Sch\u00f6rg B, Fiz F, et al. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive\u2002in vivo18F-FDG-PET.\u2002Theranostics. 2020;10(2):925\u201337.","DOI":"10.7150\/thno.35989"},{"key":"1024_CR38","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnumed.109.070946","volume":"51","author":"A Ribas","year":"2010","unstructured":"Ribas A, Benz MR, Allen-Auerbach MS, et al. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010;51:340\u20136.","journal-title":"J Nucl Med"},{"key":"1024_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","volume":"124","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31\u201382.","journal-title":"Adv Cancer Res"},{"key":"1024_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21:345\u201359.","journal-title":"Nat Rev Cancer"},{"key":"1024_CR41","first-page":"293","volume":"03","author":"Q Zhang","year":"2024","unstructured":"Zhang Q. Research and Progress of Bone Marrow Suppression Induced by Anti-Tumor Therapy. J Clin Pers Med. 2024;03:293\u20139.","journal-title":"J Clin Pers Med"},{"key":"1024_CR42","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1172\/JCI97973","volume":"128","author":"C Wu","year":"2018","unstructured":"Wu C, Ning H, Liu M, et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J Clin Invest. 2018;128:3425\u201338.","journal-title":"J Clin Invest"},{"key":"1024_CR43","doi-asserted-by":"publisher","first-page":"105818","DOI":"10.1016\/j.intimp.2019.105818","volume":"75","author":"K Jiang","year":"2019","unstructured":"Jiang K, Li J, Zhang J, et al. SDF-1\/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy. Int Immunopharmacol. 2019;75:105818.","journal-title":"Int Immunopharmacol"},{"key":"1024_CR44","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6:362.","journal-title":"Signal Transduct Target Ther"},{"key":"1024_CR45","doi-asserted-by":"publisher","first-page":"e70231","DOI":"10.1002\/mco2.70231","volume":"6","author":"T Hu","year":"2025","unstructured":"Hu T, Zhai J, Yang Z, et al. Myeloid-Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations. MedComm. 2025;6:e70231.","journal-title":"MedComm"},{"key":"1024_CR46","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/sj.bjc.6605348","volume":"101","author":"Y Kishida","year":"2009","unstructured":"Kishida Y, Kawahara M, Teramukai S, et al. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03. Br J Cancer. 2009;101:1537\u201342.","journal-title":"Br J Cancer"},{"key":"1024_CR47","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.lungcan.2006.08.001","volume":"54","author":"U Banerji","year":"2006","unstructured":"Banerji U, Ashley S, Coward J, et al. The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. Lung Cancer. 2006;54:371\u20137.","journal-title":"Lung Cancer"},{"issue":"10","key":"1024_CR48","first-page":"1757","volume":"45","author":"K Shitara","year":"2009","unstructured":"Shitara K, Matsuo K, Takahari D, et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.\u2002Eur. J Cancer. 2009;45(10):1757\u201363.","journal-title":"J Cancer"},{"key":"1024_CR49","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ygyno.2007.10.012","volume":"108","author":"RP Rocconi","year":"2008","unstructured":"Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Barnes MN. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. Gynecol Oncol. 2008;108:336\u201341.","journal-title":"Gynecol Oncol"},{"key":"1024_CR50","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.7150\/thno.75847","volume":"12","author":"S Kraus","year":"2002","unstructured":"Kraus S, Klassen P, Kircher M, et al. Reduced splenic uptake on 68Ga-Pentixafor-PET\/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis. Theranostics. 2002;12:5986\u201394.","journal-title":"Theranostics"},{"key":"1024_CR51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5152\/TurkThoracJ.2017.16025","volume":"18","author":"G Ege Aktas","year":"2017","unstructured":"Ege Aktas G, Sarikaya A, Soyluoglu Demir S. Diffusely increased splenic fluorodeoxyglucose uptake in lung cancer patients. Turk Thorac J. 2017;18:6\u201310.","journal-title":"Turk Thorac J"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01024-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01024-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01024-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:02:43Z","timestamp":1778040163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01024-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01024-w","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective study was approved by the local ethics committee of Shandong Cancer Hospital and Institute (No.SDZLEC2023-256-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}